Dell Stock Hits Record High After Trump Endorsement, AI Server Demand Fuels Rally 
CoreWeave Q1 2026 Revenue Surges as AI Infrastructure Demand Grows 
U.S.-China Beef Trade Deal Hopes Rise Ahead of Trump-Xi Summit 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
Sony Forecasts Lower 2027 Profit Despite Strong Music and Sensor Growth 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Broadcom Eyes $35 Billion AI Chip Financing Deal With Apollo and Blackstone 
Gold Prices Rise as Weaker Dollar and U.S.-Iran Peace Hopes Boost Demand 
Japan’s Yen Intervention and BOJ Rate Hike Bets Support Currency Recovery 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
China EV Truck Boom Accelerates as Iran War Drives Diesel Prices Higher 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Dollar Slips as Strong U.S. Jobs Data Reduces Fed Rate Cut Expectations 
Malaysia Unveils Energy Security Plan Amid Iran Conflict and Rising Oil Costs 
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
